Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
HRS2398
- Development stage
- Phase 2
- Lead developer
- Shanghai Hengrui Pharmaceutical Co., Ltd.
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
HRS2398 is an orally administered small molecule inhibitor targeting ATR (ataxia telangiectasia and Rad3-related) protein. It is being developed by Shanghai Hengrui Pharmaceutical for the treatment of advanced solid tumors. The drug acts as an ATR protein inhibitor, a mechanism that disrupts DNA damage response pathways in cancer cells, potentially enhancing the efficacy of anti-tumor therapies. Clinical development has reached phase Ib/II trials, both as monotherapy and in combination with other agents such as adebrelimab. The primary indications under investigation are advanced malignant tumors and solid tumors.
02
Targets
ATR (ATR serine/threonine kinase)
Beyond the preview
Go deeper on HRS2398.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on HRS2398.